PEAR THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.000001 USD | -99.00% |
|
-.--% | -.--% |
| Mar. 22 | Disclosure Statement and Plan Approved on Interim Basis for Pear Therapeutics, Inc. | CI |
| Mar. 04 | Combined Liquidation Plan and Disclosure Statement Filed by Pear Therapeutics, Inc. | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 |
|---|---|---|
| Capitalization 1 | 854.4 | 164.7 |
| Enterprise Value (EV) 1 | 706.8 | 143 |
| P/E ratio | -10.8 x | -2.17 x |
| Yield | - | - |
| Capitalization / Revenue | 203 x | 13 x |
| EV / Revenue | 168 x | 11.3 x |
| EV / EBITDA | -6.83 x | -1.24 x |
| EV / FCF | -10,284,266 x | -2,227,988 x |
| FCF Yield | -0% | -0% |
| Price to Book | 9.45 x | 5.42 x |
| Nbr of stocks (in thousands) | 137,799 | 139,543 |
| Reference price 2 | 6.200 | 1.180 |
| Announcement Date | 3/29/22 | 3/31/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Net sales 1 | 32.56 | 9.384 | 4.208 | 12.69 |
| EBITDA 1 | -31.39 | -76.21 | -103.4 | -115.1 |
| EBIT 1 | -31.6 | -76.64 | -105.7 | -119.1 |
| Operating Margin | -97.05% | -816.75% | -2,511.53% | -938.18% |
| Earnings before Tax (EBT) 1 | -9.334 | -97.02 | -65.14 | -75.49 |
| Net income 1 | -9.334 | -97.02 | -65.14 | -75.49 |
| Net margin | -28.67% | -1,033.92% | -1,548.05% | -594.7% |
| EPS 2 | -0.6324 | -7.321 | -0.5748 | -0.5442 |
| Free Cash Flow | - | -24.62 | -68.72 | -64.18 |
| FCF margin | - | -262.41% | -1,633.18% | -505.61% |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 9/8/21 | 9/8/21 | 3/29/22 | 3/31/23 |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 |
|---|---|---|---|---|---|
| Net sales 1 | 1.32 | 2.749 | 3.297 | 4.083 | 2.565 |
| EBITDA 1 | -33.58 | -33.86 | -31.85 | -25.6 | -28.23 |
| EBIT 1 | -34.23 | -34.74 | -32.82 | -26.63 | -29.16 |
| Operating Margin | -2,593.48% | -1,263.77% | -995.45% | -652.19% | -1,136.84% |
| Earnings before Tax (EBT) 1 | 18.75 | -23.86 | 5.462 | -30.72 | -26.37 |
| Net income 1 | 18.75 | -23.86 | 5.462 | -30.72 | -26.37 |
| Net margin | 1,420.45% | -867.92% | 165.67% | -752.46% | -1,028.11% |
| EPS 2 | 0.1300 | -0.1700 | 0.0400 | -0.2200 | -0.1900 |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 3/28/22 | 5/16/22 | 8/11/22 | 11/14/22 | 3/31/23 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Net Debt 1 | - | - | - | - |
| Net Cash position 1 | 89.3 | 98.1 | 148 | 21.7 |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | -24.6 | -68.7 | -64.2 |
| ROE (net income / shareholders' equity) | - | -117% | -73.4% | -125% |
| ROA (Net income/ Total Assets) | - | -39.6% | -40.1% | -50.9% |
| Assets 1 | - | 245.1 | 162.5 | 148.2 |
| Book Value Per Share 2 | -4.470 | -16.50 | 0.6600 | 0.2200 |
| Cash Flow per Share 2 | 1.860 | 10.00 | 1.230 | 0.3400 |
| Capex 1 | 0.28 | 3.9 | 3.28 | 3.47 |
| Capex / Sales | 0.86% | 41.56% | 77.9% | 27.34% |
| Announcement Date | 9/8/21 | 9/8/21 | 3/29/22 | 3/31/23 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 142 | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- PEARQ Stock
- Financials Pear Therapeutics, Inc.
